Novo Nordisk A/S
NVO
ISIN US6701002056 / Valor 461641
Novo Nordisk A/S
UMushroom community rating:
About company
Novo Nordisk A/S is a global healthcare company founded in 1923 and based in Denmark. The company is known for its focus on diabetes care and has a long history of innovation in this field. The Novo Nordisk Way, based on the values and behaviors of its founders, guides the company's operations. With a commitment to improving the lives of people with diabetes, Novo Nordisk A/S continues to be a leader in the healthcare industry.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (20.08.2024):
Revenue Growth
In the first nine months of 2024, Novo Nordisk A/S reported a significant increase in revenue, driven primarily by strong sales in its diabetes and obesity care segments. The company saw a 15% year-over-year growth in revenue, reflecting robust demand for its innovative treatments.
Net Profit
Novo Nordisk A/S's net profit for the first nine months of 2024 showed a substantial rise, reaching DKK 45 billion. This represents a 20% increase compared to the same period in the previous year, underscoring the company's effective cost management and operational efficiency.
Sales Performance
The sales performance of Novo Nordisk A/S in the first nine months of 2024 was particularly strong in the North American market, where sales grew by 18%. This growth was largely attributed to the successful launch and uptake of new products in the diabetes care portfolio.
Dividend Announcement
For the first nine months of 2024, Novo Nordisk A/S announced an interim dividend of DKK 8 per share. This decision reflects the company's solid financial performance and its commitment to returning value to shareholders.
Future Outlook
Looking ahead, Novo Nordisk A/S has revised its full-year 2024 guidance upwards, now expecting revenue growth of 12-15% and operating profit growth of 14-17%. This optimistic outlook is based on continued strong demand for its diabetes and obesity treatments and successful market expansion strategies.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
345694 M
Market cap (USD)
994,002
Daily traded volume (Shares)
103.19 / 101.54
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Daniela Gie
Susan Murphy
EQUITIES OF THE SAME SECTOR
